TY  - GEN
AU  - Fritsch,K
AU  - Kasenda,B
AU  - Schorb,E
AU  - Hau,P
AU  - Bloehdorn,J
AU  - Möhle,R
AU  - Löw,S
AU  - Binder,M
AU  - Atta,J
AU  - Keller,U
AU  - Wolf,H-H
AU  - Krause,S W
AU  - Heß,G
AU  - Naumann,R
AU  - Sasse,S
AU  - Hirt,C
AU  - Lamprecht,M
AU  - Martens,U
AU  - Morgner,A
AU  - Panse,J
AU  - Frickhofen,N
AU  - Röth,A
AU  - Hader,C
AU  - Deckert,M
AU  - Fricker,H
AU  - Ihorst,G
AU  - Finke,J
AU  - Illerhaus,G
TI  - High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
SN  - 1476-5551
PY  - 2017///1009
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Central Nervous System Neoplasms
KW  - diagnosis
KW  - Female
KW  - Humans
KW  - Immunologic Factors
KW  - administration & dosage
KW  - Lymphoma
KW  - Male
KW  - Methotrexate
KW  - Neoplasm Staging
KW  - Proportional Hazards Models
KW  - Quality of Life
KW  - Remission Induction
KW  - Treatment Outcome
KW  - Tumor Burden
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/leu.2016.334
ER  -